Development of a High Efficacy Vaccine against P. falciparum Malaria

Oxford researchers are building a vaccine that attacks the malaria parasite at multiple points in its life cycle, rather than just one. Malaria kills hundreds of thousands of children each year in sub-Saharan Africa, and existing vaccines offer only partial protection. The parasite’s complex life cycle—shifting between mosquito and human hosts, and changing form inside the body—has made it difficult for a single vaccine to stop it completely. This project targets several stages of that cycle, aiming to block infection early and prevent severe disease later. If successful, the combination vaccine could reduce deaths and illness in regions where malaria is endemic, lowering the burden on already stretched healthcare systems. The work is a direct push toward a practical tool, not a fundamental science exploration; the team plans to test the candidates in phase IIb trials in Africa.